重组型纤溶酶原激活剂联合神经介入治疗缺血性脑血管病的临床效果分析  

Clinical efficacy analysis of recombinant plasminogen activator combined with neurointerventional therapy for ischemic cerebrovascular disease

作　　者：魏建国 马双喜 WEI Jianguo;MA Shuangxi(Department of Neurology,Luoyang Sixth People's Hospital,Luoyang Henan 471000,China)

机构地区：[1]洛阳市第六人民医院神经内科,河南洛阳471000

出　　处：《天津药学》2025年第2期214-217,共4页Tianjin Pharmacy

摘　　要：目的探讨在缺血性脑血管病(ICVD)患者中实施重组型纤溶酶原激活剂联合神经介入治疗的效果。方法选择洛阳市第六人民医院2021年12月至2023年12月收治的140例ICVD患者,根据随机数字表法分成两组。对照组(n=70)予以重组型纤溶酶原激活剂治疗,观察组(n=70)在对照组的基础上予以神经介入治疗。对比两组的临床效果、神经功能、血管狭窄情况、病变血管再通情况、并发症发生率。结果治疗后,观察组的总有效率(95.71%)比对照组(84.29%)高(P<0.05),美国国立卫生研究院卒中量表(NIHSS)(8.89±2.40)分、收缩期峰值流速(Vs)(35.06±2.86)cm/s、舒张末期流速(Vd)(120.15±3.92)cm/s均低于对照组的(12.12±2.96)分、(38.97±3.28)cm/s、(134.72±4.16)cm/s(P<0.05),病变血管再通率(97.14%)比对照组(82.86%)高(P<0.05),并发症发生率(5.71%)比对照组(14.29%)低(P<0.05)。结论在ICVD患者中应用重组型纤溶酶原激活剂联合神经介入治疗,可提高疗效,改善患者的神经功能、血管狭窄、病变血管再通情况,减少并发症。Objective To investigate the effect of recombinant plasminogen activator combined with neurointerventional therapy in patients with ischemic cerebrovascular disease(ICVD).Methods A total of 140 patients with ICVD admitted to Luoyang Sixth People's Hospital from December 2021 to December 2023 were randomly divided into two groups according to the random number table method.Control group(n=70)was treated with recombinant plasminogen activator,while observation group(n=70)was treated with neurointerventional therapy on the basis of control group.The clinical effect,nerve function,vascular stenosis,vascular recanalization and complications were compared between the two groups.Results After treatment,the total effective rate of the observation group(95.71%)was higher than that of the control group(84.29%)(P<0.05).The National Institutes of Health Stroke Scale(NIHSS)was(8.89±2.40)points,systolic peak velocity(Vs)was(35.06±2.86)cm/s,and end-diastolic velocity(Vd)was(120.15±3.92)cm/s in the observation group,which were lower than those in the control group[(12.12±2.96)points,(38.97±3.28)cm/s,(134.72±4.16)cm/s](P<0.05).The revascularization rate of the observation group(97.14%)was higher than that of the control group(82.86%)(P<0.05).The complication rate of the observation group(5.71%)was lower than that of the control group(14.29%)(P<0.05).Conclusion The application of recombinant plasminogen activator combined with nerve interventional therapy in ICVD patients can improve the therapeutic effect,improve the nerve function,vascular stenosis and vascular recanalization of the patients,and reduce complications.

关 键 词：缺血性脑血管病 重组型纤溶酶原激活剂 神经介入治疗 临床效果 神经功能 血管狭窄情况 

分 类 号：R473[医药卫生—护理学]